Building tomorrow's antibody-drug conjugates (ADCs)

Araris Biotech AG is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich pioneering a novel antibody-drug conjugate (ADC)-linker technology. Our linker platform enables the attachment of any payload to ‘off the shelf’ antibodies without the need of prior antibody engineering. Learn more

Antibody-drug conjugate (ADC)

Latest news:

09/09/20 — Araris ranks 13th at Swiss Startup Award

Meet us @:

26 – 29/10/20 — Philipp will be at BIO Europe Digital
03/11/20 — European Antibody Congress 2020 - Talk by Philipp
10/11/20 — PEGS Europe Virtual - Talk by Philipp

ADCs are powerful biopharmaceuticals, delivering highly potent drugs very specifically to the desired tissue

ADCs consist of highly potent cytotoxic agents conjugated to antibodies through a specific linker. This molecular format enables the highly selective delivery of any payload to the diseased tissue, while healthy parts of the human body are spared. To date, ADCs generated with conventional methods have faced the following challenges:

Our solution: Araris Linker Technology

We are pioneering a technology enabling fast and precise production of ADCs. Our innovative approach has the potential to set new benchmarks in terms of development, analysis and performance. The following properties contribute to the high efficacy and low level of toxicity observed so far with our ADCs:

Figure

Parent antibody can be used ‘off-the-shelf’

No need for engineering or antibody reduction.

  • reduced cost and time for ADC development – less than 2 days for payload attachment
  • amenable to high-throughput screening
  • clear defined drug-to-antibody-ratio (DAR2 or DAR4) obtained

Araris LINKERs show excellent solubility (hydrophilic) and offer an unparalleled chemical versatility

  • Enables any payload to be conjugated to any antibody without major optimization
  • Straightforward incorporation of chemical functional (reactive) groups into the linker to attach payloads by different means (azide, sulfhydryl et.) thanks to its peptidic nature

Araris ADCs are very stable in serum and under stressed conditions

This may lead to lower dosing, higher efficacy and lower risk for side effects.

Araris team

Dr. Philipp Spycher

Dr. Philipp Spycher Co-founder and CEO (Board, Management team)

As the inventor of the Araris Linker Technology, Philipp has a profound background in Bioconjugation and ADCs. He obtained his Master’s Degree and PhD from ETH Zurich at the interface of Material Science and Protein Engineering. During his post-doctoral work at PSI, he introduced the novel approach using transglutaminases for antibody conjugation that led to the discovery of the Araris Linker Technology.

Dr. Isabella Attinger-Toller

Dr. Isabella Attinger-Toller Co-founder and VP Translational Research (Management team)

Isabella holds a Master’s Degree in Molecular Biology from University of Basel and obtained a PhD in Tumorimmunology from University of Zurich (UZH). Before joining Araris, she served as Director Pharmacology at Covagen, a Swiss Biotech that was acquired in 2014 by Cilag GmbH International, an affiliate of the Janssen Pharmaceutical companies of Johnson & Johnson. She was in charge of the pharmacological characterization of various FynomAbs during pre-clinical development that entered clinical testing.

Dr. Dragan Grabulovski

Dr. Dragan Grabulovski Co-founder and Chairman (Board)

Dragan received his Master’s degree and PhD in Pharmaceutical Sciences from ETH Zürich. From 2007 to 2014 he was co-founder and CSO of Covagen, a Swiss biotech company acquired in 2014 by an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson. He was instrumental in Covagen’s trade sale to Johnson & Johnson, in establishing deals with Roche and Mitsubishi Tanabe and in the closing of Covagen’s CHF 45M ($44.5M) Series B round in 2014. Since 2015 he is a serial entrepreneur and Biotech consultant at Grabulovski Consulting Services.

Prof. Dr. Roger Schibli

Prof. Dr. Roger Schibli Co-founder

Roger received his PhD in organic chemistry at the University of Basel, followed by a post-doctoral fellowship at the University of Missouri-Columbia. Since 2010, Roger holds a full professorship at the Department of Chemistry and Applied Biosciences (ETH Zurich) and heads the Center for Radiopharmaceutical Sciences ETH-PSI-USZ. Roger pioneered the use of transglutaminases for the site-specific modification of antibodies in his labs at PSI and ETH Zurich more than 10 years ago and is author of many key scientific publications in that area of research. Roger supports us with his in-dept knowledge about enzymatic modifications of antibodies as well as linker design which is core to the Araris Linker Technology. 

Dr. Martin Behe

Dr. Martin Behe Co-founder

Martin received his PhD in anorganic chemistry at the University of Basel. He worked at the University Hospitals in Göttingen, Marburg and Freiburg in Germany where he established a group for peptide-based radiopharmaceuticals and its production. Since 2011, Martin leads the Pharmacology group at PSI, where the Araris Linker Technology took its first steps. Martin has an extensive background in peptide chemistry, peptide labelling and conjugation as well and critically contributed to development of radio-labelled compounds that are used in the clinic. 

.

Meet all the founders

We are backed by a strong investor syndicate: redalpine | Schroder Adveq | VI Partners

What's new

Araris ranks 13th at Swiss Startup Award 09/09/20

Araris ranks among the TOP15 Swiss startups in 2020.  This is a great achievement for our young company - thanks jury for voting for us! Rank 95 in 2019, Rank 13 in 2020. Thank you Araris Team for your hard work. 

Meet Philipp and our team at 'Meet Venture Leaders' 03/08/20

Fun insights about our CEO and the Araris Crew... 

Araris CEO pitches in front of US investors 29/06/20

Pitch session organized by the American Embassy. A great opportunity to present, thanks Venturelab and Ambassador McMullen for the organization. 

Araris chosen as one of the "Venture Leaders Life Sciences 2020" winners 22/04/20

We are very proud to be chosen among 60 high quality applicants and are looking forward to the experience and learing on the roadshow in Boston. 

Clinical-stage Transglutaminase company Zedira releases article on Araris Technology 20/02/20

Zedira published a high level summary on the core of the Araris Linker Technology.

Araris Biotech AG establishes Scientific Advisory Board 03/10/19

Araris Biotech AG announced today the appointment of Dr. Rakesh Dixit, Dr. John Lambert and Dr. L. Nathan Tumey as members of its Scientific Advisory Board.

Araris announces closing of seed financing round 20/08/19

Araris announces closing of CHF2.5M seed financing round with participation of Swiss investors Redalpine, Schroder Adveq and VI Partners.

Araris Biotech AG wins 130000 Venture Kick III support 24/06/19

The Venture Kick jury awards MOBBOT and Araris Biotech 130,000 francs each to accelerate the engineering startup and drug-discovery spin-off's speed-to-market. The Swiss startups’ innovations in material science and biotech will benefit the construction and pharmaceutical industries.

Araris Biotech AG incorporation 31/01/19

Araris Biotech AG announces its incorporation on January 31st 2019.

Show all

Contact

Araris Biotech AG, c/o ETH Zürich Otto-Stern-Weg 7, 8093, Zürich, Switzerland

How to get to us

Subscribe

Aquisition

Please select all the ways you would like to hear from Araris Biotech AG:

You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.